Trials / Conditions / Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma

13 registered clinical trials studyying Metastatic Cutaneous Melanoma — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastat NCT07183852	Vastra Gotaland Region	Phase 1
Recruiting	Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and M NCT06391099	Ohio State University Comprehensive Cancer Center	N/A
Recruiting	Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial NCT07155317	Emory University	Phase 2
Recruiting	Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophospham NCT07130032	EuroCityClinic LLC	Phase 2
Recruiting	Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285	Mayo Clinic	Phase 2
Not Yet Recruiting	Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases NCT05903937	Vastra Gotaland Region	Phase 1
Completed	Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Met NCT04812470	Vastra Gotaland Region	Phase 1
Withdrawn	A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metas NCT05572463	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1 / Phase 2
Recruiting	Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positiv NCT05098210	Fred Hutchinson Cancer Center	Phase 1
Recruiting	A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab i NCT04511013	SWOG Cancer Research Network	Phase 2
Terminated	Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype NCT04375527	Jonsson Comprehensive Cancer Center	Phase 2
Active Not Recruiting	Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizuma NCT02506153	National Cancer Institute (NCI)	Phase 3
Terminated	Drosophila-generated CTL NCT01271907	National Cancer Institute (NCI)	Phase 2